“And in the next twelve to fifteen months, we'll end up with the phase one readout from the solid tumors in terms of the safety expansion cohorts.”
→ Read the source episode
StepPharma releases phase one solid tumor safety expansion cohort readout data
Andy Parker predicts StepPharma will move lymphoma trial into safety expansion cohort and make phase two decisions by end of 2026.
Andy Parker predicts ET trial will recruit 50 patients by summer 2027 and be phase three ready by end of 2027.
Andy Parker predicts StepPharma will complete ET phase two by end of 2027 and begin planning phase three.
Andy Parker predicts StepPharma will raise additional funding within next six months (by January 2027).
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.